A Study of AZD2962 for Blood Cancers
This study is testing a new medicine called AZD2962, which is an IRAK4 inhibitor (a type of body protein blocker), for people with certain blood cancers (haematologic neoplasms). The study aims to find out how safe AZD2962 is, how well your body handles it, and if it shows early signs of helping to treat these cancers. You might be able to join if you are 18 to 110 years old and have myelodysplastic syndromes (MDS) or dysplastic chronic myelomonocytic leukemia (CMML) that has come back or not responded to previous treatments. The main goals are to track any side effects and how long people take the medicine. The study is currently looking for about 72 participants.
- Study design
- This study will start with a dose escalation of AZD2962 given alone to participants. It is a modular study, meaning it has different parts.
- What's involved
- You will have a screening period of up to 21 days, followed by treatment cycles where you take AZD2962 by mouth once daily. Treatment continues until your disease gets worse, side effects are too much, or you decide to stop.
- Compensation
- Not stated in the trial record.
- Follow-up
- After your last dose of AZD2962, you will be followed for safety for about 30 days. The overall safety follow-up could last up to approximately 3 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
At a glance
Conditions
Where it's being run
21 sites across 8 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of participants with dose limiting toxicity (DLT)From Cycle 1 Day 1 up to end of Cycle 1 (28 Days)
A DLT is defined as an adverse event or abnormal laboratory value occurring during the DLT-evaluation period (first 28 days of treatment). This will be evaluated to assess the safety and tolerability and also to identify optimal biological dose (OBD) of AZD2962.
- Number of participants with Adverse events (AEs) and serious AEsCycle 1 Day 1 up to safety follow-up (30 days after last dose) (Approximately 3 years)
To assess the safety and tolerability of AZD2962 and also to identify OBD of AZD2962.
- Duration of exposureCycle 1 Day 1 up to safety follow-up (30 days after last dose) (Approximately 3 years)
To assess the safety and tolerability of AZD2962, and also to identify OBD of AZD2962.
- Relative dose intensityCycle 1 Day 1 up to safety follow-up (30 days after last dose) (Approximately 3 years)
To assess the safety and tolerability of AZD2962, and also to identify OBD of AZD2962.